Avadel Pharma

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avadel Pharma reports robust Q3 revenue, eyes market expansion

Avadel Pharma's Q3 performance showed solid revenue and positive EBITDA, with strong patient demand for LUMRYZ.
Despite legal challenges and competition, opportunities exist in market expansion and new patient segments.
The company's focus on persistency, market growth, and product efficacy positions it for future success.
Maintaining strong payer coverage and cash flow positivity are key priorities for upcoming quarters.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

DUBLIN, Ireland, Sept.  24, 2019  (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, for narcolepsy, today announced pharmacokinetic (PK) data for FT218 from four Phase 1 studies comparing 4.5g and 6g of once-nightly FT218 to 4.5g and 6g of twice-nightly sodium oxybate, evaluating the food effect of FT218, as well as determining the dose proportionality of FT218. The data will be included in an oral presentation by leading sleep expert, Dr. Michael Thorpy, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center, which is titled, “The Pharmacokinetics of once-nightly controlled-release sodium oxybate (FT218): Overview of results from four Phase 1 Studies,” at the World Sleep 2019 Congress on Thursday, September 25th, in Vancouver, Canada.

Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th

Micro-cap biotech Avadel Pharmaceuticals PLC (NASDAQ: AVDL) was adding about one-half to its market capitalization Monday on roughly 27 times the average trading volume.

Why Shares of Micro-Cap Biotech Avadel Are Ripping Higher

Avadel Pharmaceuticals PLC shares  soared about 22% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has agreed to reduce the sample size in a phase 3 trial of a treatment for narcolepsy.

Avadel Pharma shares soar 22% premarket after FDA cuts sample size in trial of narcolepsy treatment

DUBLIN, Ireland, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center, will be providing an oral presentation highlighting the pharmacokinetic (PK) data for Avadel’s FT218 from four Phase 1 studies at the World Sleep 2019 Congress, which is taking place from September 20-25, 2019 at the Vancouver Convention Centre, Vancouver, Canada. Data will be presented on the pharmacokinetic comparison of 4.5 and 6 g of once-nightly FT218 to 4.5 g and 6 g of twice-nightly sodium oxybate, the food effect of FT218, as well as dose proportionality data on FT218.

Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th

DUBLIN, Ireland, Sept.  17, 2019  (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today announced that its Chief Executive Officer, Greg Divis, will present at the Ladenburg Thalmann 2019 Healthcare Conference in New York City on Tuesday, September 24, 2019, at 12:00 p.m. ET.

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q2 2019 Results - Earnings Call Transcript

Dose response and pharmacokinetics data in FT218 are excellent.

Avadel Pharmaceuticals' Promising FT218 Trial Offsets Decline In Its Legacy Business

Avadel Pharmaceuticals (AVDL) Interim CEO Greg Divis on Q1 2019 Results - Earnings Call Transcript

Avadel Pharmaceuticals (AVDL) CEO Greg Divis on Q4 2018 Results - Earnings Call Transcript

News for Avadel Pharma Stock (AVDL)